Skip to content

Effect of Medical Hypnosis in Virtual Reality on Insomnia Disorders

Effect of Medical Hypnosis in Virtual Reality on Insomnia Disorders: a Monocentric, Randomized, Open-label, Comparative Study.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04712825
Acronym
EMERITE
Enrollment
20
Registered
2021-01-15
Start date
2020-12-08
Completion date
2022-11-30
Last updated
2023-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia Chronic

Keywords

Virtual reality, Hypnosis, Sleep

Brief summary

The prevalence of chronic insomnia is 13.3% in France in 2019 (8.9 million). The consequences for these people are multiple: drowsiness, memory problems, difficulty concentrating, anxiety. Cognitive and Behavioral Therapy (CBT) is today the reference treatment recommended by the Haute Autorité de Santé and the American College of Physicians for chronic insomnia. Today, however, few patients use CBT treatment due to the lack of trained practitioners, the cost of non-reimbursed sessions and the time and involvement that these sessions require. Several clinical trials have shown beneficial effects of hypnotherapy on sleep disorders. The hypothesis of this work is that the use of hypnosis in virtual reality improves sleep time in patients suffering from insomnia disorders.

Interventions

Cognitive-behavioural therapy sessions during 6 weeks of treatment

DEVICEHypnoVR® device

HypnoVR® sessions during 6 weeks of treatment

Sponsors

HypnoVR
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1\. Patient suffering from insomnia as defined in the Diagnostic and Statistical Manual of Mental Disorders V (DMS-V) and the International Classification of Sleep Disorders.

Exclusion criteria

1. Patient who, in the judgment of the investigator, has a disease that may preclude participation in study procedures. 2. Minor subject 3. Subject under judicial protection, guardianship or curatorship 4. Inability to give informed information about the subject: demented patients, psychotic patients or follow-up for a psychiatric pathology 5. Unbalanced epilepsy 6. Hearing and/or visual disorders that contraindicate the use of virtual reality headphones 7. Patient with a language barrier 8. Pregnant or breastfeeding patient 9. Subject in period of exclusion (determined by a previous or current study) 10. Patient Refusal 11. Patient currently being treated for depression, alcoholism or drug addiction. 12. Patient using drug treatment for insomnia not stabilized within 2 weeks prior to the start of the study. 13. Patient starting psychological, complementary or alternative medicine treatment for insomnia within 2 weeks prior to the start of the study, or during the study. 14. Patient receiving or having received CBT treatment for insomnia within the last 6 months. 15. Patient diagnosed with sleep apnea, involuntary limb movement, restless legs syndrome. 16. Patient with diagnosed medical conditions that cause insomnia: psychotic disorder, bipolar disorder, dementia, generalized anxiety disorder, panic disorder, manic disorder, schizophrenia, cancer.

Design outcomes

Primary

MeasureTime frameDescription
Time to sleepafter 6 weeks of treatmentDemonstrate a decrease in time to sleep after treatment, by polysomnography

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026